Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

TRACON Pharmaceuticals, Inc. (TCON)

1.49   -0.02 (-1.32%) 11-25 12:56
Open: 1.5 Pre. Close: 1.51
High: 1.51 Low: 1.49
Volume: 2,399 Market Cap: 33(M)

Technical analysis

as of: 2022-11-25 2:00:47 PM
Overall:       
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 1.84     One year: 1.99
Support: Support1: 1.36    Support2: 1.13
Resistance: Resistance1: 1.57    Resistance2: 1.71
Pivot: 1.5
Moving Average: MA(5): 1.46     MA(20): 1.52
MA(100): 1.78     MA(250): 2.07
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 39     %D(3): 32.4
RSI: RSI(14): 45.1
52-week: High: 3.78  Low: 1.24
Average Vol(K): 3-Month: 75 (K)  10-Days: 82 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ TCON ] has closed above bottom band by 45.6%. Bollinger Bands are 23.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.52 - 1.53 1.53 - 1.53
Low: 1.47 - 1.47 1.47 - 1.48
Close: 1.5 - 1.51 1.51 - 1.52

Company Description

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

Headline News

Tue, 22 Nov 2022
Surprise purchases at Sasnak City: The Gathering 2022 were worth it - Claire and Jamie

Mon, 21 Nov 2022
TRACON Pharmaceuticals Announces Dosing of First Patient in Phase 1/2 Trial of YH001 in Combination with Envafolimab and Doxorubicin in Front Line Sarcoma - Yahoo Finance

Mon, 14 Nov 2022
Tracon: Q3 Earnings Snapshot - CTPost

Mon, 14 Nov 2022
TRACON Pharmaceuticals, Inc. (TCON) Q3 2022 Earnings Call Transcript - Seeking Alpha

Sun, 13 Nov 2022
Notable earnings after Monday's close - Seeking Alpha

Thu, 10 Nov 2022
Hisense Launches Laser TV White Paper with Economist Impact, Benefitting Society Through Laser Display Technology - PR Newswire UK

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 21 (M)
Shares Float 13 (M)
% Held by Insiders 8.5 (%)
% Held by Institutions 47.6 (%)
Shares Short 151 (K)
Shares Short P.Month 130 (K)

Stock Financials

EPS -1.81
EPS Est Next Qtl -0.5
EPS Est This Year -1.58
EPS Est Next Year -1.84
Book Value (p.s.) -0.12
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -70.9
Return on Equity (ttm) -367.9
Qtrly Rev. Growth 0
Gross Profit (p.s.) -0.51
Sales Per Share 0
EBITDA (p.s.) -1.39
Qtrly Earnings Growth 0
Operating Cash Flow -27 (M)
Levered Free Cash Flow -15 (M)

Stock Valuations

PE Ratio -0.83
PEG Ratio 0
Price to Book value -12.42
Price to Sales 0
Price to Cash Flow -1.2

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2019-11-07
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.